-+ 0.00%
-+ 0.00%
-+ 0.00%

ABBVIE'S TELISOTUZUMAB ADIZUTECAN (TEMAB-A) RECEIVES TWO BREAKTHROUGH THERAPY DESIGNATIONS FROM THE U.S. FDA FOR CRC AND NSCLC

路透·10/07/2026 12:30:06

請登錄查看新聞詳情